May 21st 2010
Women with ovarian cancer have few nonplatinum-based chemotherapy options. At the 33rd ESMO Congress in September 2008, researchers
reported findings from OVA-301, a phase III trial that compared efficacy and safety of trabectedin (Yondelis) in combination with
pegylated liposomal doxorubicin (PLD) versus PLD monotherapy in women with relapsed ovarian cancer.